Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBL-020 in advanced malignant tumors
NCT05877924Phase 1Recruiting
- Sponsor
- NovaRock Biotherapeutics
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of NBL-020 in advanced malignant solid tumor and cutaneous T-cell lymphoma (CTCL), sponsored by NovaRock Biotherapeutics. Primary endpoint: Adverse Events. Started Aug 2023; status: recruiting.
02
Drugs
NBL-020
03
Conditions
advanced malignant solid tumorcutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT05877924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05877924.